Format

Send to

Choose Destination
Cancer Lett. 2006 Aug 28;240(2):221-4. Epub 2005 Dec 27.

The anti-obesity agent Orlistat is associated to increase in colonic preneoplastic markers in rats treated with a chemical carcinogen.

Author information

1
Department of Pathology, Ribeirão Preto Medical School, University of São Paulo, USP, Avenida Bandeirantes 3900, 14049-900 Ribeirão Preto, SP, Brazil. sbgarcia@fmrp.usp.br

Abstract

Orlistat is an anti-obesity agent that increases the fecal fat excretion, which promotes colon carcinogenesis. Therefore, the present study was designed to verify the effects of Orlistat on the formation of rat colonic aberrant crypt foci (ACF) and cell proliferation evaluated by the PCNA method. Male Wistar rats received either a standard diet or a high fat diet (HFD), supplemented or not with Orlistat (200mg/kg chow) and two doses of the carcinogen dimethyl-hydrazine (25mg/Kg). After 30 days, Orlistat was associated to a significant increase in the number of colonic ACFs and cell proliferation in DMH-treated animals, independently of the HFD.

PMID:
16377080
DOI:
10.1016/j.canlet.2005.09.011
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center